GLP-1 receptor agonists are approved for the treatment of type 2 diabetes, and more recently for\nobesity treatment. The glucagon-like-peptide-1 (GLP-1) is a glucose dependent hormone produced\nby intestinal cells, which is involved in insulin secretion and glucagon suppression. This hormone\ncontrols glucose plasma levels and reduces food intake. Additional effects were reported in slowing\ngastric emptying and in inducing satiety. In clinical practice, the GLP-1 receptor agonists are\nassociated with significant reductions in glycosylated hemoglobin (HbA1c) and weight loss, despite\nshowing a low risk of hypoglycemia. Beneficial effects have also been observed on blood pressure\nand lipid profile. The most common side effects associated with GLP-1 receptor agonists are gastrointestinal\nmotility disorders, such as nausea, vomiting and diarrhea, which are not associated with\nlong-term health risks. Therefore, GLP-1 receptor agonists represent a relevant medication for type\n2 diabetes, whose benefits may go far beyond glycemic control.
Loading....